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Whenever there is a European Parliamentary Technology As­
sessment (EPTA) meeting, such as this one, held at the Parlia­
ment of Catalonia on 23 October 2012 (‘From Genes to Jeans: 
Challenges on the Road to Personalised Medicine’), the audi­
ence is a complex mixture. These meetings are attended by 
scientists, members of parliaments, and representatives of the 
advisory boards of the various EPTA organizations, who may 
or may not be scientists. Consequently, EPTA meetings bring 
together a diversity of approaches, views, and outlooks. 
As a member of the Institute for Catalan Studies, the catalan 
academy of sciences and humanities, I am well aware that the 
strength of a culture, of a language, of a country, does not de­
pend on the number of square kilometers that it spans or on 
the size of its population. Rather, it is based mainly on the 
strength of the fruits of that culture and its language. As Cata­
lans we are another culture in west Mediterranean Europe of 
the 21st century. Núria de Gispert, president of the Parliament 
of Catalonia voiced these sentiments in her introduction to this 
meeting. Ours is an old country and merits the same rights as 
Germany, Italy, or Spain. We have our own language, and our 
roots in the Mediterranean can be traced back over centuries. 
As a crosswalk of civilizations throughout our history, we are an 
open people. We are also Europeans and we will go together 
with all of you, the peoples of Europe.
After the wealth of information presented during this 2012 
EPTA meeting focusing on personalised medicine, it is a difficult 
task to briefly summarize the conclusions of the many expert 
speakers. The term personalised medicine refers to the applica­
tion of genomic and molecular data to patients in order to es­
tablish the correct diagnosis and the most suitable treatment for 
each person. The main challenge to implementing personalised 
medicine is its complexity. Healthcare systems are already 
overwhelmed; but their sustainability is possible only if they are 
able to make the transition from data collection to data integra­
tion. In the common clinical practice, the skilled physician al­
ready applies personalised medicine to each patient, treating 
him or her as a unique individual. Indeed, despite the many 
technological advancements that facilitate the generation of a 
plethora of biochemical and physiological data, in daily clinical 
practice medical treatment has always been personalised.
While considering recent technological advances, it is a 
good idea to remember Lewis Thomas (1913–1993), author of 
The Lives of a Cell, and The Medusa and the Snail, among other 
books. He held appointments at several medical schools and 
hospitals and ended his professional career serving as the 
chancellor of the Memorial Sloan­Kettering Cancer Center, in 
New York City. In The Youngest Science (1983), he recalls how 
he became acquainted with the medical daily work by accom­
panying his father, a general practitioner in Long Island, in the 
1920s. The senior Dr. Thomas made unending house calls and 
wrote his prescriptions in Latin. By the time his son Lewis at­
tended medical school, in the 1930s, medicine had changed 
and was no longer a practice but was rapidly becoming a hard 
science. And by the 1990s, when Lewis Thomas died, the sci­
ence of medicine had changed beyond recognition, with the 
diagnosis, treatment, and cure of many diseases that were 
previously deemed intractable. He remembers his father say­
ing: “Medicine always tries to cure by attending to the particular 
biological characteristics. No patient is the same as another.” 
This way of thinking, of seeing the patient as an individual, has 
a long tradition in medicine and it must be maintained, regard­
less of technological advances. 
The main objective of personalised medicine in the modern 
genomics era is the study of the individual genetic variability, 
the predisposition of a patient to a particular disease, and his or 
her response to the pharmacological agents used in the treat­
ment. The ideal drug, one that is effective in every patient, does 
not exist. For a physician, it can be difficult to assume the effi­
cacy of a drug or a given dose in one patient because the pa­
tient has the ‘same’ health disorder or ‘similar’ symptoms as 
another patient; forgetting this fact may be not only inadequate 
but even harmful. In many cases, the lack of efficiency of a par­
ticular drug is caused by the patient’s genetic characteristics, 
which determine the drug’s absorption, metabolism, and ex­
cretion. In the next few decades, clinical medicine, with its 
growing focus on patient­tailored treatments, will increasingly 
need to take these factors into account. 
The development of methodologies that allow the rapid 
and inexpensive sequencing of individual genomes allows us 
to think that personalised medicine will soon become a reali­
ty. Two of the many anticipated benefits are sparing patients 
ineffective treatments and avoiding adverse side effects. 
Consequently, we will avoid unnecessary suffering as well as 
higher healthcare costs. This aspect was commonly pointed 
out by many of the speakers at this meeting. Also frequently 
noted was that the successful implementation of personal­
ised medicine would only be possible with continuous re­
search efforts in all the new ‘­omics’ sciences. 
Pharmacogenetics and, more widely, pharmacogenomics 
are the sciences upon which personalised medicine will be 
based. The most important changes in the development of 
new drugs will be linked to the necessity of simultaneously de­
veloping a diagnostic assay and a targeted treatment. Fulfil­
ment of the promises of pharmacogenomics has implications 
far beyond purely the scientific ones; it will require a radical 
change in the way medicine is currently practiced.
The synergy of pharmacogenomics, biotechnology, and 
regulatory approaches should be considered an asset if per­
sonalised medicine is to succeed. Furthermore, the ethical, le­
gal, and social consequences must be fully recognized, and 
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fulfilled. There is also an urgent necessity for both public and 
private investment, and collaboration between the two. We live 
in a complex networking society in which the functioning of 
each node depends on that of the others.
I would like to end these brief comments with a quote by 
André Gide’s (1869–1951) that was mentioned in one of the 
lectures: “Toutes choses sont dites déjà, mais comme personne 
n’écoute, il faut toujours recommencer.” (Everything is already 
said, but since no one was listening, everything must be said 
again.) There are many challenges both in the introduction of 
innovations into the healthcare system and in their long­term 
adoption. But, as the confused married woman in Woody Al­
len’s To Rome with Love (2012), who, when faced with temp­
tation, says: “If I try, perhaps I will be sorry for some time, but 
if I don’t try, I will be sorry forever,” personalised medicine is 
definitely an enterprise worth trying. And it is also a challenge 
for all EPTA members who attended this meeting. Let us go 
forward, spread the news, and, when we meet again in Fin­
land next year, discuss the insights and experience we have 
gained here and now.
